1Toloza EM, Harpole L, McCrory DC, et al. Noninvasive staging of non- small cell lung cancer: a review of the current evidence [ J]. Chest, 2003,123(1 ) :137.
2Kim HY, Yi CA, Lee KS, eL al. Nodal metastasis in non-small cell lung cancer : accuracy of 3.0-T MR imaging (J). Radiology, 2008, 246(2) :596.
3Prenzel K L, Monig S P, Sinning J M, et al. Lymph node size and metasratic infiltration in non-small cell lung cancer[ J]. Chest,2003, 123(2) :463.
4Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-mo- dality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomo- graphy and computed (FDG-PFT/CT) for tumor staging in solid tumors:comparison with CT and PET[ J]. J Clin Oncol, 2004,22 (21) :4357.
5Antoch G, Vogt FM, Freudenberg LS, et al. Whole-bodydual-modality PET/CT and whole-body MRI for tumor staging in oncology [ J]. JA- MA ,2003,290 (24) :3199.
6Zielinski M. Transcervical extended mediastinallymphadenectomy : re- sults of staging in two hundred fifty-six patients with non-small cell lung cancer[ J ]. J Thorac Oncol,2007,2 (4) :370.
7Shrager JB. Mediastinoscopy : still the gold standard [ J ]. Ann Thorac Surg,2010,89 (6) :2084.
8Grunenwald D, Le Chevalier T. Re : Stage Ⅲ A category of nonsmall cell lung cancer: a new proposal (J). J Natl Cancer Inst, 1997,89 (1) :88.
9Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer [ J ]. Semin Oncol, 1997,24 (4) :429.
10Casali C,Stefani A,Natali P,et al. Prognostic factors in surgically re- sectcd N2 non-snmlt cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases [ J ]. Eur Cardiothorac Surg, 2008,28( 1 ) :33.
2De Craene S,Sunnont V,van Meerbeeck JP. Adjuvant or neoadjuvant chemotherapy in minimal N2 stage m A nonsmall cell lung cancer [J]. Current Opinion in Oncology,2010,22 (2) :102-111.
3Singh T,Katiyar SK. Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2 -Mediated Activation of β-Catenin Signaling [J]. PLoS One, 2013,8 (4) : e60749.
4Baba T,Uramoto H,Takenaka M,et al. Prognostic factors before and after recurrence of resected non-small cell lung cancer [J]. Respir Investig, 2012,50 (4) : 151-156.
5Dellamore A,Monteverde M, Caroli G, et al. Surgical results and survival of older patients with unsuspected N2 (stage Ⅲ A)non-small cell lung cancer [J]. G Chir,2013,34 (3):53- 58.
6Ettinger DS,Akerley W,Borghaei H. Non-small cell lung cancer [J]. J Natl Compr Canc Netw,2012,10 (10) : 1236- 1271.
7Prenzel KL,Bollschweiler E,Schrder W,et al. Prognostic relevance of skip metastases in esophageal cancer [J]. Ann Thorac Surg, 2010,90 (5) : 1662-1667.
8Hanagiri T,Takenaka M, Oka S,et al. Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage Ⅲ-N2 non-small cell lung cancer [J]. J Cardiothorac Snrg,2011,6:144.
9Bartheld MB,Versteegh MI, Braun J,et al. Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer [J]. J Thorac Oncol, 2011,6(9) : 1510-1515.
